Travere Operating Margin from 2010 to 2025

TVTX Stock  USD 21.98  1.60  6.79%   
Travere Therapeutics Operating Profit Margin yearly trend continues to be fairly stable with very little volatility. Operating Profit Margin will likely drop to -1.44 in 2025.
Check Travere Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Travere Therapeutics' main balance sheet or income statement drivers, such as Selling General Administrative of 320.6 M, Other Operating Expenses of 581.5 M or Total Operating Expenses of 584.9 M, as well as many indicators such as Price To Sales Ratio of 6.84, Dividend Yield of 0.0 or PTB Ratio of 22.1. Travere financial statements analysis is a perfect complement when working with Travere Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Travere Therapeutics Correlation against competitors.
For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.

Latest Travere Therapeutics' Operating Margin Growth Pattern

Below is the plot of the Operating Profit Margin of Travere Therapeutics over the last few years. It is Travere Therapeutics' Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Travere Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (0.79) %10 Years Trend
Slightly volatile
   Operating Profit Margin   
-0.5700-0.3800-0.6100-1.1900-2.5900-1.3800-1.4400100%
       Timeline  

Travere Operating Margin Regression Statistics

Arithmetic Mean(1.51)
Geometric Mean1.11
Coefficient Of Variation(71.82)
Mean Deviation0.96
Median(1.19)
Standard Deviation1.08
Sample Variance1.17
Range2.4826
R-Value0.47
Mean Square Error0.97
R-Squared0.22
Significance0.07
Slope0.11
Total Sum of Squares17.53

Travere Operating Margin History

2025 -1.44
2024 -1.38
2023 -2.59
2022 -1.19
2021 -0.61
2020 -0.38
2019 -0.57

About Travere Therapeutics Financial Statements

Travere Therapeutics investors use historical fundamental indicators, such as Travere Therapeutics' Operating Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Travere Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. Travere Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 310 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Travere Stock Analysis

When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.

Trending Assets

STOK
Stoke Therapeutics
8.33  -0.41  -4.69 
NUVL
Nuvalent
79.49  -2.9  -3.52 
GPCR
Structure Therapeutics
23.77  0.38  1.62 
LEGN
Legend Biotech Corp
39.70  0.78  2.00 
RNA
Avidity Biosciences
31.12  -1.41  -4.33 
VTYX
Ventyx Biosciences
1.61  -0.05  -3.01 
RVMD
Revolution Medicines
41.34  -0.92  -2.18 
FIXX
FIXX Old
0.00  0.00  0.00 
KROS
Keros Therapeutics
11.02  -0.01  -0.09 
PCVX
Vaxcyte
79.74  -2.73  -3.31 
COGT
Cogent Biosciences
8.00  -0.09  -1.11 
DICE
Dice Molecules Holdings
0.00  0.00  0.00 
PTGX
Protagonist Therapeutics
38.75  0.26  0.68 
MGTX
MeiraGTx Holdings PLC
7.30  0.47  6.88 
ANAB
AnaptysBio
18.59  -0.28  -1.48 
IDYA
Ideaya Biosciences
21.85  0.12  0.55 
CYTK
Cytokinetics
50.26  -0.86  -1.68 
CERE
Cerevel Therapeutics
0.00  0.00  0.00 
APLS
Apellis Pharmaceuticals
27.52  -0.83  -2.93 
AKRO
Akero Therapeutics
51.84  1.26  2.49 
N…I…